Skip to main content

Postoperative Bowel & Ileus Management — Drug-Class Hub

Postoperative ileus (POI) is the rate-limiting complication of any GU operation that touches bowel — urinary diversion (ileal conduit, orthotopic neobladder, Mainz, Indiana), augmentation cystoplasty, continent catheterizable channels, and large pelvic reconstruction with bowel interposition (omental, colonic, ileal). POI occurs in 15–27% of post-diversion patients and is the leading cause of prolonged hospitalization and readmission.[1][2][3] Although colon recovers motility in 3–5 days, small bowel in 24 hours, and stomach in 24–48 hours, it is colonic dysmotility that rate-limits the postoperative course.[5]

This article is the drug-class pharmacology hub — agents, mechanisms, doses, indication-by-indication evidence, and safety ceilings. The clinical workflow for post-op constipation and ileus management — bowel prep, ERAS prophylactic regimens, stepped escalation, and the PAMORA framework — lives at Postoperative constipation & ileus, and should not be re-derived here. Use the two together: workflow on one page, pharmacology on this one.

For adjacent topics see NSAIDs & analgesics (opioid-sparing analgesia), ERAS, and Nausea & vomiting.

Drug-Class Overview at a Glance​

Class / agentMechanismBest-supported roleEvidence strength
PAMORA — AlvimopanPeripheral μ-opioid receptor antagonist (blocks GI opioid effect without crossing BBB)POI prevention after open bowel-segment GU surgeryHigh — pivotal RCT + Cochrane + real-world[6][7][8]
Prokinetic — MetoclopramideD₂ antagonist; sensitizes upper GI to AChAntiemetic with modest upper-GI prokinetic effectLow for POI; moderate for PONV[10][12][13]
Prokinetic — NeostigmineAChE inhibitorAcute colonic pseudo-obstruction (Ogilvie) — the definitive indicationHigh for ACPO; low for routine POI[21][22][23]
Stimulant laxative — BisacodylProdrug → antiabsorptive, secretory, prokinetic on colonScheduled postop laxative POD 1–2 onwardModerate in colorectal; extrapolated[17]
Stimulant laxative — SennaAnthraquinone stimulantAlternative stimulant; often combined with docusateModerate — pelvic-reconstruction RCT[20]
Stool softener — DocusateAnionic surfactantNot recommended as monotherapyIneffective vs placebo[19]
Anti-foaming — SimethiconeSurfactant (gas coalescence)Comfort measure for bloating; not prokineticNegative RCT[15]
Osmotic laxative — PEGOsmotic draw into colonProphylactic perioperative laxativeModerate in urologic-cancer cohort[29]
Non-pharmacologic — Gum chewingVagal cholinergic "sham feeding"Universal adjunct POD 0–1 onwardModerate — 2 cystectomy RCTs + NMA[24][25][26]
Non-pharmacologic — CoffeeMultimodal colonic stimulation (beyond caffeine)Universal adjunct POD 0–1 onwardModerate — NMA[26][28]

1. Alvimopan (Entereg) — The Highest-Impact Single Agent​

Alvimopan is the best-studied pharmacologic agent for POI prevention after open bowel-segment GU surgery and the only drug with a prospectively demonstrated effect on GI recovery time, length of stay, and POI rate in a cystectomy-with-diversion RCT.[6]

Mechanism​

Peripherally acting μ-opioid receptor antagonist (PAMORA) — K_i 0.4 nM at the μ receptor, with slower dissociation kinetics than other μ ligands. Does not cross the blood-brain barrier, so it blocks opioid-induced GI dysmotility while preserving central analgesia from perioperative opioids.[4]

Dosing​

  • 12 mg PO 30 min – 5 h before surgery, then 12 mg PO twice daily starting POD 1 until discharge
  • Maximum 15 total doses or 7 days — whichever comes first
  • Inpatient use only through the Alvimopan REMS Program[4]

Efficacy in radical cystectomy with urinary diversion​

Lee 2014 pivotal multicenter RCT (n = 277):[6]

  • GI-2 recovery (first solid food + BM): 5.5 vs 6.8 days (HR 1.8; p < 0.0001)
  • Length of stay: reduced by ~2.7 days
  • POI rate: significantly reduced vs placebo
  • Cochrane 2017 review confirmed the effect size with moderate-certainty evidence[7]

Real-world and ERAS-integrated data​

  • Belle 2019 Vizient database (n = 7,472 cystectomies 2014–2016) — alvimopan utilization increased 35% → 59%; associated with decreased perioperative morbidity (10.5% vs 19.2%; p = 0.027)[8]
  • Hanna 2021 — added to existing ERAS, alvimopan further reduced LOS 9 → 7 days (p = 0.003), GI recovery 5 → 4 days (p = 0.018), POI 28.4% → 14.6% (p = 0.005)[1]
  • Benefit most pronounced with open surgery; in robotic cohorts (where baseline POI is already lower, ~4.5% vs 27.5% with open) the incremental benefit is attenuated or absent[1][3]

Alhashemi 2021 systematic review: low-to-moderate certainty evidence for open bowel resection and open cystectomy with diversion; very-low-certainty for MIS. This is the framework for patient selection — alvimopan is strongly supported for open, uncertain for robotic.[9]

Safety and the FDA boxed warning​

FDA Boxed Warning

A 12-month trial of alvimopan 0.5 mg BID for chronic non-cancer pain showed a greater incidence of myocardial infarction vs placebo. A causal relationship has not been established, and this imbalance was not seen in short-term surgical use (alvimopan 12 mg, n = 1,142 vs placebo, n = 1,120).[4] Alvimopan is therefore restricted to short-term inpatient use only (≤ 15 doses, ≤ 7 days) through the REMS program.

Contraindications​

  • Therapeutic opioid use for > 7 consecutive days immediately before surgery (PAMORA paradoxically worsens symptoms in opioid-tolerant patients)
  • Severe hepatic impairment (up to 10-fold higher plasma levels)
  • ESRD — not studied
  • Complete GI obstruction
  • Pancreatic or gastric anastomoses — not studied[4]

Most common AE: dyspepsia (1.5% vs 0.8% placebo).[4]

Other PAMORAs​

For opioid-induced constipation outside the immediate perioperative window — especially in patients on chronic opioids for pelvic pain, IC/BPS flares, or oncologic survivorship — methylnaltrexone, naloxegol, and naldemedine are the relevant agents. See the PAMORA framework on Postoperative constipation & ileus for indication-by-indication detail.

2. Metoclopramide — Antiemetic with Modest Upper-GI Prokinetic Effect​

Mechanism​

D₂-receptor antagonist that sensitizes GI tissues to ACh — ↑ gastric antral contractions, pyloric relaxation, and duodenal / jejunal peristalsis. Little to no colonic effect — a meaningful limitation because colonic dysmotility is the rate-limiting step in POI.[10][11]

Evidence in urinary-diversion surgery​

Donat 1999 (n = 81 post-cystectomy-diversion) — combined IV metoclopramide with early NG tube removal (< 72 h):[12]

  • Faster return of bowel sounds: 2.9 vs 4.0 days (p = 0.0002)
  • Earlier solid food tolerance: 6.7 vs 7.9 days (p = 0.04)
  • ↓ atelectasis: 15% vs 33% (attributable to early NG removal)

Bungard 1999 review — no literature supports metoclopramide reducing POI duration; limited data confounded by small samples and insensitive endpoints.[13]

Current ERAS role​

  • Included in ~44% of published radical-cystectomy ERAS protocols — the second most common pharmacologic anti-ileus measure after gum chewing[14]
  • Primary role is PONV prophylaxis with modest prokinetic adjunct, not primary POI prevention
  • Monotherapy is insufficient for POI

Dosing and safety​

ElementDetail
Dose10 mg IV q6–8 h; 10–20 mg IM for PONV[10]
FDA boxed warningTardive dyskinesia with prolonged use (> 12 weeks)
Other AEsExtrapolidal symptoms (particularly young patients), QT prolongation
Perioperative ceilingShort-term postoperative use only

3. Neostigmine — For Acute Colonic Pseudo-Obstruction, Not Routine POI​

Neostigmine has a specific, defined role in urology: treatment of acute colonic pseudo-obstruction (ACPO / Ogilvie syndrome), which can complicate major pelvic GU surgery. It is not appropriate for routine POI prophylaxis.[23]

Mechanism​

Acetylcholinesterase inhibition → ↑ ACh at muscarinic receptors throughout the GI tract → stimulates colonic motility.

Evidence in ACPO — strong​

Both the ASCRS 2021 guideline and ASGE 2020 guideline recommend neostigmine as the pharmacologic agent of choice when ACPO does not resolve with conservative management (Strong recommendation, 1B).[21][22]

  • Ponec 1999 landmark RCT (NEJM) — 10 / 11 patients (91%) receiving 2 mg IV neostigmine had clinical response at median 4 minutes (range 3–30 min) vs 0 / 10 placebo patients
  • Meta-analysis: single IV 2–5 mg dose → 60–94% success; recurrence 0–31%; overall long-term response 69–100%[22]
  • Second dose for initial nonresponders → effective in 40–100%[22]

ACPO protocol​

ElementDetail
First-line conservative managementNG decompression, NPO, correct electrolytes, stop opioids / anticholinergics, mobilize
Neostigmine indicationFailed conservative management ×48–72 h, cecal diameter approaching 12 cm, or clinical deterioration[21]
Dose2–2.5 mg IV bolus over 3–5 min; continuous infusion (0.4–0.8 mg/h × 24 h) for refractory cases; SC (0.25–1 mg) alternative[22]
Mandatory monitoringContinuous cardiac monitoring — bradycardia 5–9%
Antidote at bedsideAtropine or glycopyrrolate must be available

Adverse effects​

  • Abdominal pain 50–73%
  • Sialorrhea 23–38%
  • Vomiting 10–20%
  • Bradycardia 5–9%[21][22]

Contraindications​

Mechanical bowel obstruction, urinary obstruction, bradycardia, asthma, recent MI.[21][22]

Routine POI — not indicated​

The Traut 2008 Cochrane review of systemic prokinetics for POI found neostigmine "might show effects" on recovery time, but the evidence was limited to small trials of moderate-to-poor quality. Neostigmine is not recommended for routine POI prophylaxis — its role is reserved for established ACPO or refractory ileus after expert assessment.[23]

4. Stimulant Laxatives — Bisacodyl and Senna​

Bisacodyl — the scheduled colonic-stimulant laxative of choice in post-GU-surgery ERAS:

Mechanism​

Prodrug hydrolyzed by intestinal brush-border enzymes into an active metabolite with antiabsorptive, secretory, and prokinetic effects on the colon.[16]

Evidence​

Zingg 2008 colorectal RCT (n = 169):[17]

  • GI-3 recovery (first flatus + first defecation + solid food): 3.0 vs 3.7 days (p = 0.007)
  • First defecation: 3.0 vs 4.0 days (p = 0.001)
  • No difference in first flatus or solid-food tolerance
  • No difference in morbidity / mortality

Wallström 2014 systematic review classified bisacodyl's effect on overall bowel motility as "uncertain" in colorectal surgery — accelerated defecation, did not consistently improve other GI recovery parameters.[18]

ASCRS/SAGES ERAS guidelines recommend stimulant laxatives as second-line therapy after osmotic laxatives for constipation management, with bisacodyl preferred for achieving complete spontaneous bowel movements at 4 weeks vs prescription prokinetics.[16]

Dose and use​

Bisacodyl 10 mg PO or PR daily, typically starting POD 1–2 within the scheduled ERAS bowel regimen.[16][17]

Senna — alternative anthraquinone stimulant. Patel 2010 RCT in post–pelvic-reconstructive surgery (n = 63) — senna + docusate combination reduced time to first BM 3.0 vs 4.05 days (p = 0.03).[20] The combination is standard in many post-urogynecologic-reconstruction protocols.

5. Docusate — De-prescribe as Monotherapy​

Mechanism​

Anionic surfactant; emulsifies stool. No prokinetic activity.

Evidence — negative​

Systematic reviews conclude docusate is no more effective than placebo for preventing constipation.[19] It does not lessen associated symptoms (abdominal cramps) or improve stool-evacuation perception.

The inertia problem​

A JAMA Intern Med study documented that despite published inefficacy, docusate accounted for 64% of total laxative administration at one facility, driven by clinical inertia, low unit cost, and historical practice. An educational intervention successfully reduced docusate use.[19]

Practical recommendation​

Do not prescribe docusate as monotherapy for postoperative constipation. If used, it should be combined with a stimulant laxative (senna or bisacodyl). Many institutions are actively de-prescribing.

6. Simethicone — Comfort Measure, Not Prokinetic​

Mechanism​

Non-absorbed surfactant reducing surface tension of GI gas bubbles → facilitates coalescence and passage. Does not stimulate motility.

Evidence​

SPOT trial (n = 118, colorectal surgery) — the only RCT specifically for POI:[15]

  • First flatus: 25.2 vs 26.7 h (p = 0.98)
  • First BM: 41.1 vs 42.9 h (p = 0.91)
  • LOS: 4.5 vs 4.0 days (p = 0.63)

Practical role​

Symptomatic relief of bloating and gas pain only. Excellent safety profile (non-absorbed, no systemic effects) makes it a low-risk comfort-only addition.

7. Osmotic Laxatives and Prophylactic Laxative Use​

Wahafu 2025 real-world cohort (n = 1,724 urologic-cancer surgery patients):[29]

  • Prophylactic laxative use (started preop or immediately postop) reduced constipation 12.3% vs 42.7% (HR 0.24; 95% CI 0.19–0.30; p < 0.001)

For the GU-reconstructive population, PEG 3350 17 g daily or senna + bisacodyl combination starting POD 1 are the two most common ERAS prophylactic regimens. See the workflow at Postoperative constipation & ileus.

8. Non-Pharmacologic Adjuncts — Gum Chewing and Coffee​

Low-cost, safe, evidence-supported additions to any GU-reconstruction ERAS pathway.

Gum chewing ("sham feeding")​

Vagal cholinergic stimulation + ↑ saliva production.

  • Kouba 2007 (cystectomy n = 102) — flatus 2.4 vs 2.9 d; BM 2.9 vs 3.4 d[24]
  • Choi 2011 (cystectomy n = 60, open + robotic) — flatus 57.1 vs 69.5 h; BM 76.7 vs 93.3 h[25]
  • Sinz 2023 NMA (32 RCTs, n = 4,999) — gum chewing ↓ flatus 11 h, defecation 18 h, LOS 0.9 d[26]
  • ASCRS/SAGES ERAS gives gum chewing a strong recommendation (1B) — sugar-free, ≥ 10 min, 3–4× daily[27]

Coffee​

Multimodal colonic stimulation — caffeine is not the primary driver. Chlorogenic acids, melanoidins, and other non-caffeine components contribute.

  • Sinz 2023 NMA — coffee ↓ defecation 13 h, LOS 1.5 d[26]
  • Zheng 2025 meta — decaffeinated coffee was the most effective intervention for ↓ time to first defecation and ↓ LOS — suggesting non-caffeine components drive the prokinetic effect[28]

Evidence Summary — What Actually Changes Outcomes​

ComponentGI recoveryLOSPOI rateEvidence strength
Alvimopan (open cystectomy-diversion)↓ 1.3 d[6]↓ 2.7 d[1][6]28.4% → 14.6%[1]High (RCT + Cochrane + real-world)
NG tube avoidance—↓ 8.7 d[30]—High (IPD meta)
Multimodal ERAS package↓ 1.4 d[30]↓ 3.5 d[30]Complications ↓ 24%[30]High
Gum chewingFlatus ↓ 11 h[26]↓ 0.9 d[26]—Moderate (NMA + 2 RCTs)
Coffee (incl. decaf)Defecation ↓ 13 h[26][28]↓ 1.5 d[26]—Moderate (NMA)
Prophylactic laxatives——Constipation 42.7% → 12.3%[29]Moderate (large cohort)
BisacodylGI-3 ↓ 0.7 d; defecation ↓ 1 d[17]——Moderate (colorectal RCT)
MetoclopramideBowel sounds ↓ 1.1 d; solid food ↓ 1.2 d[12]——Low (1 cystectomy study; no POI benefit on SR)
Simethicone———Negative RCT[15]
Docusate———Placebo-equivalent[19]
Neostigmine(ACPO-specific)——High for ACPO[21][22]; not for routine POI[23]

Cross-Reference — What's Covered on the Perioperative Constipation/Ileus Page​

To avoid duplication, these topics live at Postoperative constipation & ileus:

TopicWhere it lives
Bowel preparation (mechanical ± oral antibiotics, by GU procedure type)Perioperative-care page
ERAS prophylactic bowel regimen (scheduled laxative stack, NG avoidance, early feeding)Perioperative-care page
Stepped management of established ileus — NG, bowel rest, imaging, surgical vs medical thresholdsPerioperative-care page
PAMORA framework beyond alvimopan — methylnaltrexone, naloxegol, naldemedine for chronic OICPerioperative-care page
Drug-class pharmacology and doses for each agentThis article
Alvimopan boxed warning / contraindications / REMS detailThis article
Neostigmine ACPO protocolThis article

Keep the two separate: workflow on the perioperative-care page, drug-class pharmacology here.

Practical Pearls​

  • Alvimopan is the single highest-impact pharmacologic intervention for POI after open GU surgery with bowel-segment reconstruction — LOS ↓ 2.7 d, GI recovery ↓ 1.3 d, POI rate roughly halved.[1][6][7]
  • Alvimopan's benefit is attenuated in robotic diversion — baseline POI is already low (~4.5% vs 27.5% open); consider patient-by-patient rather than universal alvimopan use in MIS.[1][3]
  • Contraindicated if opioids were given for > 7 days preoperatively — this is the most common real-world exclusion.[4]
  • NG tube avoidance may outperform any single drug — IPD meta ↓ LOS 8.7 d, larger than any pharmacologic intervention.[30]
  • Docusate should be de-prescribed — placebo-equivalent, adds pill burden and cost.[19]
  • Stimulant laxatives first, softeners only in combination. Bisacodyl 10 mg PO/PR POD 1 onward; senna + docusate pair if using docusate at all.[16][17][20]
  • Neostigmine is for ACPO, not routine POI. When cecal diameter approaches 12 cm after 48–72 h of failed conservative management, 2–2.5 mg IV over 3–5 min with continuous cardiac monitoring and bedside atropine.[21][22]
  • Gum chewing and coffee (including decaf) are universal, low-cost adjuncts. Evidence supports all three.[26][28]
  • Multimodal ERAS outperforms any single intervention — bowel-prep avoidance + NG avoidance + opioid-sparing analgesia + alvimopan + early feeding + gum/coffee + scheduled laxatives + early mobilization collectively reduce LOS by 3.5 days and complications by 24%.[30]

References​

1. Hanna P, Regmi S, Kalapara A, et al. "Alvimopan as part of the enhanced recovery after surgery protocol following radical cystectomy is associated with decreased hospital stay." Int J Urol. 2021;28(6):696–701. doi:10.1111/iju.14546

2. Pang KH, Groves R, Venugopal S, Noon AP, Catto JWF. "Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy." Eur Urol. 2018;73(3):363–371. doi:10.1016/j.eururo.2017.07.031

3. Nakamura M, Tsuru I, Izumi T, et al. "Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy." Sci Rep. 2023;13(1):16237. doi:10.1038/s41598-023-43489-w

4. US Food and Drug Administration. Alvimopan — prescribing information. Updated 2026-03-31.

5. Bragg D, El-Sharkawy AM, Psaltis E, Maxwell-Armstrong CA, Lobo DN. "Postoperative ileus: recent developments in pathophysiology and management." Clin Nutr. 2015;34(3):367–376. doi:10.1016/j.clnu.2015.01.016

6. Lee CT, Chang SS, Kamat AM, et al. "Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial." Eur Urol. 2014;66(2):265–272. doi:10.1016/j.eururo.2014.02.036

7. Sultan S, Coles B, Dahm P. "Alvimopan for recovery of bowel function after radical cystectomy." Cochrane Database Syst Rev. 2017;5:CD012111. doi:10.1002/14651858.CD012111.pub2

8. Belle JD, Pooli A, Oleynikov D, Deibert CM. "Alvimopan usage increasing following radical cystectomy." World J Urol. 2019;37(6):1151–1155. doi:10.1007/s00345-018-2476-3

9. Alhashemi M, Hamad R, El-Kefraoui C, et al. "The association of alvimopan treatment with postoperative outcomes after abdominal surgery: a systematic review across different surgical procedures and contexts of perioperative care." Surgery. 2021;169(4):934–944. doi:10.1016/j.surg.2020.11.025

10. US Food and Drug Administration. Metoclopramide — prescribing information. Updated 2026-04-14.

11. Hasler WL, Katz PO, Lambiase LR. "Prokinetic pharmacology in postoperative ileus." (Contextual reference — see Bungard 1999 for SR context.)

12. Donat SM, Slaton JW, Pisters LL, Swanson DA. "Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion." J Urol. 1999;162(5):1599–1602.

13. Bungard TJ, Kale-Pradhan PB. "Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature." Pharmacotherapy. 1999;19(4):416–423. doi:10.1592/phco.19.6.416.31040

14. Wessels F, Lenhart M, Kowalewski KF, et al. "Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols." World J Urol. 2020;38(12):3139–3153. doi:10.1007/s00345-020-03133-y

15. Springer JE, Elkheir S, Eskicioglu C, et al. "The effect of simethicone on postoperative ileus in patients undergoing colorectal surgery (SPOT), a randomized controlled trial." Int J Surg. 2018;56:141–147. doi:10.1016/j.ijsu.2018.06.011

16. Alavi K, Thorsen AJ, Fang SH, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the evaluation and management of chronic constipation." Dis Colon Rectum. 2024;67(10):1244–1257. doi:10.1097/DCR.0000000000003430

17. Zingg U, Miskovic D, Pasternak I, et al. "Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial." Int J Colorectal Dis. 2008;23(12):1175–1183. doi:10.1007/s00384-008-0536-7

18. Wallström A, Frisman GH. "Facilitating early recovery of bowel motility after colorectal surgery: a systematic review." J Clin Nurs. 2014;23(1-2):24–44. doi:10.1111/jocn.12258

19. Pasay D, Guirguis M, Shkrobot R, Slobodan J, Bresee L. "Association of dissemination of an educational communication tool with docusate administration." JAMA Intern Med. 2017;177(10):1433–1436. doi:10.1001/jamainternmed.2017.3605

20. Patel M, Schimpf MO, O'Sullivan DM, LaSala CA. "The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial." Am J Obstet Gynecol. 2010;202(5):479.e1–5. doi:10.1016/j.ajog.2010.01.003

21. Naveed M, Jamil LH, Fujii-Lau LL, et al. "American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus." Gastrointest Endosc. 2020;91(2):228–235. doi:10.1016/j.gie.2019.09.007

22. Alavi K, Poylin V, Davids JS, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colonic volvulus and acute colonic pseudo-obstruction." Dis Colon Rectum. 2021;64(9):1046–1057. doi:10.1097/DCR.0000000000002159

23. Traut U, Brügger L, Kunz R, et al. "Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults." Cochrane Database Syst Rev. 2008;(1):CD004930. doi:10.1002/14651858.CD004930.pub3

24. Kouba EJ, Wallen EM, Pruthi RS. "Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion." Urology. 2007;70(6):1053–1056. doi:10.1016/j.urology.2007.07.048

25. Choi H, Kang SH, Yoon DK, et al. "Chewing gum has a stimulatory effect on bowel motility in patients after open or robotic radical cystectomy for bladder cancer: a prospective randomized comparative study." Urology. 2011;77(4):884–890. doi:10.1016/j.urology.2010.06.042

26. Sinz S, Warschkow R, Tarantino I, Steffen T. "Gum chewing and coffee consumption but not caffeine intake improve bowel function after gastrointestinal surgery: a systematic review and network meta-analysis." J Gastrointest Surg. 2023;27(8):1730–1745. doi:10.1007/s11605-023-05702-z

27. Irani JL, Hedrick TL, Miller TE, et al. "Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons." Surg Endosc. 2023;37(1):5–30. doi:10.1007/s00464-022-09758-x

28. Zheng L, Zhang X, Ma B, Yuan Y, Yang H. "Efficacy of non-pharmacological interventions for the restoration of postoperative intestinal motility of patients with colorectal cancer: a systematic review and meta-analysis of randomized controlled trials." Int J Colorectal Dis. 2025;40(1):176. doi:10.1007/s00384-025-04968-w

29. Wahafu W, Yang F, Yang T, et al. "Prophylactic laxative use for postoperative constipation in urological cancer: a real-world cohort study." World J Urol. 2025;43(1):698. doi:10.1007/s00345-025-06050-0

30. Williams SB, Cumberbatch MGK, Kamat AM, et al. "Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta-analysis." Eur Urol. 2020;78(5):719–730. doi:10.1016/j.eururo.2020.06.039